Literature DB >> 18829751

Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.

Eloìsa Yuste1, Jacqueline Bixby, Jeffrey Lifson, Shuji Sato, Welkin Johnson, Ronald Desrosiers.   

Abstract

Human immunodeficiency virus type 1 and simian immunodeficiency virus possess three closely spaced, highly conserved sites for N-linked carbohydrate attachment in the extracellular domain of the transmembrane protein gp41. We infected rhesus monkeys with a variant of cloned SIVmac239 lacking the second and third sites or with a variant strain lacking all three of SIVmac239's glycosylation sites in gp41. For each mutation, asparagine (N) in the canonical N-X-S/T recognition sequence for carbohydrate attachment was changed to the structurally similar glutamine such that two nucleotide changes would be required for a reversion of the mutated codon. By 16 weeks, experimentally infected monkeys made antibodies that neutralized the mutant viruses to high titers. Such antibodies were not observed in monkeys infected with the parental virus. Thus, new specificities were revealed as a result of the carbohydrate attachment mutations, and antibodies of these specificities had neutralizing activity. Unlike monkeys infected with the parental virus, monkeys infected with the mutant viruses made antibodies that reacted with peptides corresponding to the sequences in this region. Furthermore, there was strong selective pressure for the emergence of variant sequences in this region during the course of infection. By analyzing the neutralization profiles of sequence variants, we were able to define three mutations (Q625R, K631N, and Q634H) in the region of the glycosylation site mutations that conferred resistance to neutralization by plasma from the monkeys infected with mutant virus. Based on the reactivity of antibodies to peptides in this region and the colocalization of neutralization escape mutations, we conclude that N-linked carbohydrates in the ectodomain of the transmembrane protein shield underlying epitopes that would otherwise be the direct targets of neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829751      PMCID: PMC2593353          DOI: 10.1128/JVI.01382-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Characterization of the cis-acting elements controlling subgenomic mRNAs of citrus tristeza virus: production of positive- and negative-stranded 3'-terminal and positive-stranded 5'-terminal RNAs.

Authors:  S Gowda; T Satyanarayana; M A Ayllón; M R Albiach-Martí; M Mawassi; S Rabindran; S M Garnsey; W O Dawson
Journal:  Virology       Date:  2001-07-20       Impact factor: 3.616

2.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  A role for carbohydrates in immune evasion in AIDS.

Authors:  J N Reitter; R E Means; R C Desrosiers
Journal:  Nat Med       Date:  1998-06       Impact factor: 53.440

4.  Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.

Authors:  P Kolchinsky; E Kiprilov; P Bartley; R Rubinstein; J Sodroski
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3).

Authors:  J M Harouse; A Gettie; T Eshetu; R C Tan; R Bohm; J Blanchard; G Baskin; C Cheng-Mayer
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication.

Authors:  W E Johnson; J M Sauvron; R C Desrosiers
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.

Authors:  R E Means; R C Desrosiers
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; M Piatak; T Parks; L Li; R Kiser; V Coalter; B Fisher; B M Flynn; S Czajak; V M Hirsch; K A Reimann; J E Schmitz; J Ghrayeb; N Bischofberger; M A Nowak; R C Desrosiers; D Wodarz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 10.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

View more
  17 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Short communication: Simultaneous substitutions of V38M and N43T-N44K in the gp41 heptad repeat 1 (HR1) disrupt HIV type 1 gPr160 endoproteolytic cleavage (*).

Authors:  V A Morozov; A V Morozov; S Lagaye
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

3.  Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages.

Authors:  Elizabeth Stansell; Ronald C Desrosiers
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

4.  A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.

Authors:  Michael D Alpert; Lisa N Heyer; David E J Williams; Jackson D Harvey; Thomas Greenough; Maria Allhorn; David T Evans
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

5.  Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.

Authors:  José M Martinez-Navio; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

6.  Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge.

Authors:  Michael D Alpert; Andrew R Rahmberg; William Neidermyer; Sharon K Ng; Angela Carville; Jeremy V Camp; Robert L Wilson; Michael Piatak; Keith G Mansfield; Wenjun Li; Christopher J Miller; Jeffrey D Lifson; Pamela A Kozlowski; David T Evans
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

7.  Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.

Authors:  James M Termini; Elizabeth S Church; Zachary A Silver; Stuart M Haslam; Anne Dell; Ronald C Desrosiers
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

8.  Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.

Authors:  Li-Hua Ping; Sarah B Joseph; Jeffrey A Anderson; Melissa-Rose Abrahams; Jesus F Salazar-Gonzalez; Laura P Kincer; Florette K Treurnicht; Leslie Arney; Suany Ojeda; Ming Zhang; Jessica Keys; E Lake Potter; Haitao Chu; Penny Moore; Maria G Salazar; Shilpa Iyer; Cassandra Jabara; Jennifer Kirchherr; Clement Mapanje; Nobubelo Ngandu; Cathal Seoighe; Irving Hoffman; Feng Gao; Yuyang Tang; Celia Labranche; Benhur Lee; Andrew Saville; Marion Vermeulen; Susan Fiscus; Lynn Morris; Salim Abdool Karim; Barton F Haynes; George M Shaw; Bette T Korber; Beatrice H Hahn; Myron S Cohen; David Montefiori; Carolyn Williamson; Ronald Swanstrom
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

9.  Models of RNA virus evolution and their roles in vaccine design.

Authors:  Samuel Ojosnegros; Niko Beerenwinkel
Journal:  Immunome Res       Date:  2010-11-03

10.  Glycosylation site-specific analysis of clade C HIV-1 envelope proteins.

Authors:  Eden P Go; Qing Chang; Hua-Xin Liao; Laura L Sutherland; S Munir Alam; Barton F Haynes; Heather Desaire
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.